Read full document

Financial Analysis

  • By
  • March 29, 2005
  • 3407 Words
  • 357 Views
Page 1 of 14
1.0 Introduction

The project topic 'An Analysis of the Financial Performance of Renata Limited' is a significant one as it facilitates the understanding of the financial performance parameters of a company, on the context of a growing pharmaceuticals industry base in Bangladesh.

1.1 Origin

This report has been authorized to the students as an integral component of the Financial Management (F- 501) course requirement. The Course Instructor Mr. Imran Rahman has authorized this report on the June 7, 2003 with the date of submission being July 1, 2003.

1.2 Objectives

The objectives of the report is,

To discuss the Pharmaceutical Sector's prospect over the next one year.

To do a full analysis of the company's financial performances in the past three years.

To prepare the forecasted income statement for the next year and

To estimate the external fund requirement for the next year.

1.3 Methodology

Only secondary sources of data, which comprised the annual reports of the company of the year 2002 and 2001 has been used to do the project. The prospect for the sector has been written based on the news and information available from websites.

1.4 Scope

The scope of the report is limited to the information gathered from the Annual Reports of the Company. The performance analysis does not include any discussion with the management or the visit of the factory.

1.5 Limitation

The major limitation of the report was the lack of adequate information as the management was reluctant in divulging any information other than what is published on the annual reports.

2.0 Overview of Renata Limited

History Founded in 1972 as a subsidiary of Pfizer Inc. Ownership transferred from Pfizer Inc. to local institutions and the general public in 1993. Company name subsequently changed from Pfizer Laboratories (Bangladesh) Limited to Renata Limited.

Type of Company Listed Public Limited (Dhaka Stock Exchange).

Authorized Capital US $2.0...